Abstract
The ubiquitin-dependent proteasome system plays a critical role in many cellular processes and pathogenesis of various human diseases, including cancer. Although there are a large number of E3 ubiquitin ligases, the majority are RING-finger type E3s. Pirh2, a target of p53 transcription factor, contains a highly conserved C 3H 2C 3 type RING domain. Importantly, Pirh2 was found to regulate a group of key factors dedicated to the DNA damage response, such as p53, p73, PolH, and c-Myc. Interestingly, Pirh2 was upregulated or downregulated in different types of cancers. These suggest that Pirh2 is implicated in either promoting or suppressing tumor progression in a tissue-dependent manner. This review will focus on the major findings in these studies and discuss the potential to explore Pirh2 as a cancer therapeutic target.
Original language | English (US) |
---|---|
Pages (from-to) | 1397-1402 |
Number of pages | 6 |
Journal | FEBS Letters |
Volume | 586 |
Issue number | 10 |
DOIs | |
State | Published - May 21 2012 |
Keywords
- Cancer therapy
- E3 ligase
- Pirh2
- Tumorigenesis
ASJC Scopus subject areas
- Biochemistry
- Biophysics
- Cell Biology
- Genetics
- Molecular Biology
- Structural Biology